Globus Medical (GMED) Q2 Earnings: What To Expect

Medical device company Globus Medical (NYSE:GMED) will be reporting results this Thursday after market hours. Here’s what investors should know.

Globus Medical missed analysts’ revenue expectations by 4.7% last quarter, reporting revenues of $598.1 million, down 1.4% year on year. It was a softer quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ EPS estimates.

Is Globus Medical a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Globus Medical’s revenue to grow 17.5% year on year to $740.2 million, slowing from the 116% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.75 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Globus Medical has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Globus Medical’s peers in the medical devices & supplies - specialty segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Integer Holdings delivered year-on-year revenue growth of 11.4%, beating analysts’ expectations by 2.6%, and Bausch + Lomb reported revenues up 5.1%, topping estimates by 2.2%. Integer Holdings traded down 6.3% following the results while Bausch + Lomb was also down 7%.

Read our full analysis of Integer Holdings’s results here and Bausch + Lomb’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the medical devices & supplies - specialty stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Globus Medical is down 4.2% during the same time and is heading into earnings with an average analyst price target of $83 (compared to the current share price of $53.64).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.